Completed PHASE2 INTERVENTIONAL NCT00002773

Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer

A CLINICAL TRIAL FOR PANCREAS CANCER USING ACTIVE INTRALYMPHATIC IMMUNOTHERAPY WITH INTERFERON-TREATED PANCREAS CANCER TISSUE CULTURE CELLS, GMCSF, AND LOW-DOSE CYCLOPHOSPHAMIDE

Sponsor: St. Vincent Medical Center - Los Angeles

Conditions Pancreatic Cancer

Interventions allogeneic tumor cell vaccine cyclophosphamide recombinant interferon alfa sargramostim

Updated 5 times since 2017 Last updated: Jul 9, 2013 Started: May 31, 1996 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by St. Vincent Medical Center - Los Angeles and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Vincent Medical Center - Los Angeles

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States